Pepgen Inc (PEPG) - News Archive

for CSIMarket.com PepGen Inc.: Navigating a Strategic Pivot Amidst Legal and Market Challenges PepGen Inc. (NASDAQ: PEPG), a biopharmaceutical company, currently finds itself at a crucial juncture. Recently, the law fir...

for CSIMarket.com : PepGen Inc. s Investor Concerns Amidst Industry Competition On April 12, 2025, Pomerantz LLP initiated an investigation on behalf of investors of PepGen Inc. (NASDAQ: PEPG) following concerning finan...

In a significant development for shareholders, Pomerantz LLP, a renowned securities law firm, has initiated an investigation into potential claims on behalf of the investors of PepGen Inc (NASDAQ: PEPG). This move comes...

PepGen Inc. Navigates Course Correction in Duchenne Muscular Dystrophy Research BOSTON In a significant development for both the company and the Duchenne Muscular Dystrophy (DMD) community, PepGen Inc. (Nasdaq: PEPG), a...

Revolutionizing DMD Treatment: Updates on PepGen s CONNECT Program in the Face of Market Challenges PepGen Inc. a clinical-stage biotechnology company listed on Nasdaq under the ticker PEPG, is committed to transforming...

Turbulence in Innovation: PepGen Faces Clinical Setback Amidst Competitive Revenue GrowthIn the intricate landscape of biotechnology, where hope for transformative therapies often collides with regulatory challenges, Pe...

: This article discusses the recent financial performance and corporate developments of PepGen Inc., a clinical-stage biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological dis...

PepGen Inc., a biotechnology firm based in Boston, has reported encouraging clinical data from a low-dose cohort study of its investigational therapy, PGN-EDO51, aimed at treating Duchenne Muscular Dystrophy (DMD). This...

Duchenne muscular dystrophy (DMD) is a devastating and progressive genetic disorder that primarily affects young boys, leading to muscle weakness, loss of ambulation, and potentially life-threatening complications. Desp...

PepGen Inc. Announces Pricing of $80.1 Million Underwritten Offering of Common StockBOSTON, Feb. 07, 2024 PepGen Inc. (Nasdaq: PEPG) made a significant announcement today regarding the pricing of an underwritten offerin...

As the race to find effective treatments for Duchenne Muscular Dystrophy (DMD) continues, PepGen has recently made a significant announcement that has captured the attention of medical experts and investors alike. The c...

Biopharmaceutical company, PepGen, has announced the first successful administration of their novel drug candidate, PGN-EDODM1 to a patient. This marks the initiation of a Phase 1 clinical trial named FREEDOM-DM1, aimed...